Stroke care has advanced most clearly in the acute phase: rapid reperfusion, prevention of edema, secondary prevention, and early rehabilitation. Yet for many patients, the most difficult clinical reality begins after stabilization. Neurological recovery often improves over weeks to months, then plateaus. Once that spontaneous recovery window closes, residual motor, language, or cognitive deficits may become permanent.
A study published in Nature now identifies a molecular mechanism that may help explain why this window narrows. Researchers led by Jun Tsuyama and Takashi Shichita, PhD, at the Institute of Science Tokyo found that microglia, the brain’s resident immune cells, can remain in the post-stroke brain after losing their reparative function. The team identified ZFP384 as a transcriptional regulator that suppresses the microglial repair program and showed that blocking it with an antisense oligonucleotide improved long-term recovery in mouse models of ischemic stroke.
A repair program that fades too soon
Microglia are often discussed in the context of neuroinflammation, but their role after stroke is not uniformly harmful. In the acute phase, activated myeloid cells contribute to inflammatory injury. During recovery, however, microglia can shift toward a reparative state, producing neurotrophic and tissue-supportive factors that contribute to remyelination, synaptic remodeling, and functional improvement.
One of the key markers in this study was insulin-like growth factor 1, or IGF1, a neurotrophic factor produced by reparative microglia. IGF1 has known roles in synaptogenesis, oligodendrocyte function, and myelin repair. The researchers used IGF1 expression to track microglia involved in the recovery phase after ischemic stroke.
“We aimed to identify the molecular mechanism responsible for diminishing microglial reparative functions,” Tsuyama said in the press release.
The central observation was clinically relevant: reparative microglia did not simply disappear. Instead, lineage-tracing experiments showed that cells which had once expressed repair-associated genes persisted in the peri-infarct region but later lost that gene-expression program. In mice, recovery-associated gene expression rose after stroke and then declined toward baseline by around day 28. The cells remained, but their reparative identity faded.
ZFP384 as a brake on microglial repair
To identify what shuts down this repair state, the researchers combined RNA sequencing, single-cell RNA sequencing, ATAC-seq, and transcription-factor analysis. A protein known as ZFP384 emerged as a candidate regulator whose expression increased as the microglial repair program declined.
Functionally, ZFP384 acted as a brake. Overexpression of Zfp384 reduced Igf1 expression in microglial cells, while genetic deletion of Zfp384 in microglia sustained recovery-associated gene expression after stroke. Mice lacking Zfp384 specifically in microglia showed better long-term neurological outcomes on behavioral tests, without significant differences in infarct volume, cerebral blood flow, or survival.
That distinction is important. The intervention did not appear to reduce the initial ischemic injury. Instead, it improved the recovery phase, suggesting a therapeutic concept distinct from acute neuroprotection.
Mechanistically, the study links ZFP384 to disruption of YY1-mediated chromatin interactions. YY1 helped maintain enhancer–promoter contacts required for recovery-associated gene expression, including at the Igf1 locus. As ZFP384 increased, it displaced this repair-permissive chromatin organization, shifting microglia toward a dysfunctional state.
The authors describe this as a strategy to “prevent the loss of reparative immunity,” preserving beneficial immune-cell functions rather than broadly suppressing inflammation.
Antisense therapy improved recovery in mice
The translational component of the study used antisense oligonucleotides (ASO) designed to reduce Zfp384 expression. After intracerebroventricular administration, the ASO was taken up by microglia and reduced Zfp384 mRNA expression.
When ASO-Zfp384 was administered on days 8 and 22 after stroke onset, mice showed improved neurological recovery compared with controls. Notably, benefit was also observed when treatment began on day 29, suggesting that the approach may influence the chronic recovery phase in this mouse model rather than only early repair.
The biological readouts supported the behavioral findings. ASO-Zfp384 sustained microglial recovery-associated gene expression, increased IGF1-positive microglia in peri-infarct tissue, and promoted broader neural repair signatures in oligodendrocyte precursor cells, excitatory neurons, and astrocytes. Treated mice showed improved myelination, enhanced white matter conduction, and increased synaptic markers including synaptophysin and PSD95.
Neutralizing IGF1 or SPP1 reduced the recovery benefit, strengthening the conclusion that microglial neurotrophic factors were functionally involved.
Human tissue supports the pathway
The researchers also examined human post-mortem brain tissue from patients who had experienced ischemic stroke. In peri-infarct regions, IGF1-positive IBA1-positive cells were more abundant early after stroke and declined later. ZNF384, the human orthologue of mouse ZFP384, showed the opposite pattern, increasing later in the recovery period.
The inverse relationship between IGF1 and ZNF384 supports the relevance of the pathway in human stroke biology, although it remains correlative. The human samples do not show that ZNF384 inhibition would improve patient outcomes, but they indicate that the same molecular pattern observed in mice may also occur in the human post-stroke brain.
Implications for rehabilitation medicine
The findings point to a therapeutic space that remains underdeveloped: enhancing recovery after the acute phase. Rehabilitation depends on plasticity, remyelination, and circuit remodeling, but current pharmacological options to extend or potentiate this biology are limited.
A therapy that sustains reparative microglia could, in principle, complement rehabilitation by keeping the peri-infarct environment more permissive for repair. That would represent a different clinical goal from thrombolysis, thrombectomy, or anti-inflammatory intervention. Rather than rescuing threatened tissue in the first hours, the aim would be to improve the quality and duration of recovery over subsequent weeks.
The study remains preclinical. Delivery route, dose, safety, timing, durability, and patient selection all require further work. The mouse model cannot capture the full heterogeneity of human stroke, including lesion location, age, comorbidities, vascular risk, rehabilitation intensity, and medication use. Sustaining immune-mediated repair also needs careful safety evaluation, because prolonged activation of tissue-resident immune cells could have context-dependent risks.
Still, the concept is compelling. Microglia are not merely inflammatory cells to inhibit; they can be repair partners whose beneficial state may be actively preserved. If ZFP384-targeted approaches prove safe and effective in larger models, they could open a new class of post-stroke recovery therapies focused on extending the brain’s own repair window.
As Tsuyama put it, “sustaining the brain’s endogenous repair program” may create opportunities to reduce permanent neurological symptoms during rehabilitation.
The post Targeting Microglia Could Help Extend the Recovery Window After Stroke appeared first on Inside Precision Medicine.
